Recent Updates

November 16, 2026: Rebate Pilot Hearing Set, Medicare Part B Cut Coming

The rebate pilot court hearing is November 18, Medicare's 340B Part B cut starts January 1, and Congress is unlikely to act first. What it means for covered entities and pharmacies.

Weekly updateCovered entities & pharmaciesNovember 16, 20265 min readBy the Secure340B team

The 340B Rebate Model Pilot is still set to start January 1, 2027. The most important date before then is Wednesday, November 18, when the federal court in Maine hears arguments on the hospitals' request to block it. Congress looks unlikely to step in first. Covered entities should keep preparing for January 1 and treat a court ruling as a possible change of plans, not something to wait for.

What happened this week

  • Court hearing set for November 18. On November 6, the federal court in Portland, Maine scheduled oral argument for 9 a.m. on November 18 on the hospitals' request for a temporary restraining order. Judge Lance Walker, who blocked the first pilot in December 2025, is hearing the case. There is no ruling yet.
  • Congress is unlikely to act before January 1. On November 10, Rep. Raul Ruiz (D-Calif.) said blocking the pilot during the lame-duck session would be "very difficult." None of the bills that would delay or end the pilot has passed. Rep. Doris Matsui (D-Calif.), a lead sponsor of the PROTECT 340B Act, which would end the pilot, won reelection and could lead the House health subcommittee that oversees 340B next year.
  • The pilot itself hasn't changed. It still covers the same 10 manufacturers, all planning to use the Beacon platform.
  • A rural example of the cash impact. A study for Russell County Hospital, a 25-bed critical access hospital in Kentucky, projects that its upfront spending on pilot drugs will rise 153%, from about $346,000 to $875,000. Eliquis, Jardiance, Januvia, Vraylar and Tradjenta account for most of the increase.
  • Medicare cuts pay for 340B Part B drugs on January 1. In its 2027 hospital outpatient final rule (November 4), CMS set payment for separately payable Part B drugs bought at 340B prices at ASP minus 28%, down from ASP plus 6% today. Drugs bought outside 340B are still paid ASP plus 6%. Rural sole community, children's and PPS-exempt cancer hospitals are exempt, and critical access hospitals aren't paid under this system. Every separately payable drug line will need a modifier: JG (bought on 340B, cut applies), TB (bought on 340B, exempt) or ND (not bought on 340B).
  • CMS finalized its permanent drug price negotiation rule on November 5. It takes effect December 5 and applies to drugs negotiated for 2029 and later. CMS said it will address how the Medicare negotiated price (MFP) reaches pharmacies in separate guidance. Until then, MFP refunds continue under the current process.
  • 340B ESP now checks user access. Since November 11, ESP confirms that the person submitting a file has access to every 340B ID in it. Claims for any 340B ID that user can't access are left out of the submission.
  • Beacon's operator asks to dismiss a state lawsuit. Second Sight Solutions, which runs Beacon and 340B ESP, and 13 drugmakers asked a federal court in Arkansas to dismiss the state attorney general's 340B suit against them. Nothing changes in how either platform works today.

What this means for covered entities

  • Check that the people who submit to 340B ESP have access to every 340B ID you submit for, including child sites, so no claims are left out. In ESP, review your Entity Profile and invite users where needed.
  • Finish Beacon registration, banking and user setup now. Don't wait for the November 18 hearing.
  • Decide, drug by drug, whether to buy your Medicare Part B drugs on 340B or outside 340B. CMS says hospitals may buy outside 340B if they follow all required guidance and regulations. For each drug, compare your margin on 340B, (ASP minus 28%) minus your 340B price, with your margin outside 340B, (ASP plus 6%) minus your non-340B price. Drugs with deep 340B discounts usually still favor 340B; drugs with small discounts may not. DSH, children's and freestanding cancer hospitals can't buy outpatient drugs through a GPO, so their non-340B price is usually WAC, which narrows the gain. CMS also warned that choosing drugs to take advantage of payment differences, rather than for medical need, may raise fraud and abuse concerns: which account you buy from is a purchasing decision, but which drug a patient gets stays a clinical one. Our Medicare Part B article walks through the math with examples.
  • Set up split billing so the drugs you choose restock on the right account for Medicare patients, make sure every separately payable drug line gets the JG, TB or ND modifier, and write your decisions into your 340B policies.
  • Estimate your cash float on the pilot drugs, drug by drug: the WAC price minus the 340B price, times the days you wait for the rebate.
  • If you use CVS as a contract pharmacy, decide by December 1 whether to sign CVS's new 340B pharmacy services agreement. CVS has said it will end arrangements that aren't signed at year-end.
  • Plan for Medicare Part D 340B claims reporting. It is required for Part D claims with dates of service from January 1, 2027. The first file, covering January through June, is due September 30, 2027.

Our 2027 rebate pilot checklist walks through each step.

What this means for pharmacies

  • The new Medicare Part B cut doesn't apply to retail or contract pharmacy 340B prescriptions. It covers drugs hospitals give in their outpatient departments, so expect questions from hospital partners about purchasing and billing.
  • No change to MFP refunds this week. Keep reconciling them claim by claim and file a Good Faith Inquiry when one is missing or short.
  • Know who gets the discount when a pilot drug claim is both 340B and Medicare, starting January 1. Each manufacturer's approved plan decides, and they don't all handle it the same way:
    • When the 340B price is lower: Merck, Pfizer, Teva, Amgen, AbbVie, AstraZeneca, BMS and GSK pay the covered entity the 340B rebate and reduce the pharmacy's MFP refund. Astellas's and Boehringer Ingelheim's plans don't say.
    • When the MFP is lower: Merck, Pfizer, Teva, Amgen and, for now, GSK pay the covered entity the 340B rebate and reduce the pharmacy's MFP refund. AbbVie, AstraZeneca and BMS may reject the 340B rebate, so the pharmacy gets the full MFP refund. Astellas's and Boehringer Ingelheim's plans don't say.
  • Talk with your covered entity partners now about which claims they will flag as 340B. Agreeing early means fewer held MFP refunds and fewer denied rebates in January.

Our MFP refund guide explains how to spot and fix a missing or short refund.

How Secure340B can help

For covered entities: we estimate your January 1 cash-flow impact from your own purchasing data and get you ready for rebate claims. Start with the free 340B Rebate Readiness Quiz.

For pharmacies: we reconcile your MFP refunds claim by claim and find the missing or short ones. Start with the free MFP Rebate Readiness Quiz.

Information current as of November 16, 2026. This is general education, not legal or billing advice. Confirm coding with CMS guidance and your compliance team. Sources: Court docket, AHA v. Kennedy (D. Me.); 340B Report, Nov. 10, 2026; 340B Report, Nov. 13, 2026; Healthcare Finance News, rural hospital study; Becker's, 10 drugmakers approved; CMS CY 2027 OPPS final rule, Federal Register; Holland & Knight, CY 2027 OPPS final rule; Covington, CMS final negotiation rule; 340B ESP, Nov. 11, 2026; 340B Report, Arkansas suit; Frier Levitt, CVS 340B contracts; Covington, Part D 340B repository; manufacturer rules from HRSA-approved pilot plans.

Need help applying it?

A clearer path starts
with a conversation.

Talk with our team about your organization and the workflow that needs attention.